Registered title, quoted from ClinicalTrials.gov
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07035379, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
11. The dosage of steroid hormone (prednisone phase equivalent) used greater than 20mg/ day within 28 days prior to first administration for more than 14 consecutive days, or immunosuppressive treatment.
Exclusion criterion 11
4. ECOG performance status 0-2.
Inclusion criterion 4
3. Measurable disease of at least 15mm (node)/10mm (extranodal).
Inclusion criterion 3
2. Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load; Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load; Human immunodeficiency virus (HIV) seropositive.
Exclusion criterion 2
7. Patients with other malignancies within the past 5 years.
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07035379, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Part I: Age 18 -65 years old; Part II: Aged ≥ 18 years old, both male and female.
- 2. Previously untreated patients with CD20-positive DLBCL diagnoses by 2022 WHO.
- 3. Measurable disease of at least 15mm (node)/10mm (extranodal).
- 4. ECOG performance status 0-2.
- 5. International Prognostic Index (IPI) score of 2-5.
- 6. Estimated survival time ≥6 months.
- 7. Having sufficient organ function.
- 8. Female and male patients of childbearing age and their spouses are willing to carry out adequate contraception throughout the study period, and female patients of childbearing age must have negative serum pregnancy test within 7 days before the first administration.
- 9. Patients voluntarily agree to participate in the study and to sign the informed consent form.
Exclusion Criteria:
- 1. Contraindication to any of the individual components of study drugs, including prior receipt of xenoproteins, biological agents.
- 2. Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load; Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load; Human immunodeficiency virus (HIV) seropositive.
- 3. Clinically apparent central nervous system (CNS) lymphoma.
- 4. Patient has ≥ Grade 2 peripheral neuropathy.
- 5. Investigator-assessed diabetes uncontrolled by drug therapy.
- 6. Clinically significant third space fluid accumulation.
- 7. Patients with other malignancies within the past 5 years.
- 8. With active autoimmune diseases.
- 9. Accompanied by serious cardiovascular diseases.
- 10. Accompanied by serious diseases and serious active infections.
- 11. The dosage of steroid hormone (prednisone phase equivalent) used greater than 20mg/ day within 28 days prior to first administration for more than 14 consecutive days, or immunosuppressive treatment.
- 12. Various vaccines were inoculated within 28 days prior to first administration;
- 13. Major surgery (except diagnostic biopsy) within 28 days prior to first administration or during the study period.
- 14. Participate in clinical trials of other drugs or medical devices within 28 days prior to first administration.
- 15. Serious medical or psychiatric illness likely to interfere with participation in this study.
- 16. Investigators assessed as unsuitable to participate in this study for other reasons.
Quoted from ClinicalTrials.gov, NCT07035379, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07035379, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.